NANJING, China, May 29, 2026 — Frontier Biotech today announced the presentation of preclinical data of FB7023, a dual-target small interfering RNA (siRNA) drug candidate, at the 20th Oriental Congress of Cardiology (OCC 2026), a leading academic conference in the cardiovascular field in China

FB7023 is being developed for the treatment of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD). It targets PCSK9 and LPA, two key pathogenic factors in lipid metabolism pathways. By simultaneously intervening in these two independent causal risk factors for ASCVD, FB7023 may effectively reduce both primary and residual cardiovascular risk, with a novel mechanism of action that offers potential advantages over single-target intervention. Leveraging long-acting nature of siRNA drugs, FB7023 has the potential to improve long-term patient adherence and simplify chronic disease management.

Data presented at OCC 2026 showed that in a validated spontaneous hyperlipidemia rhesus monkey model with elevated Lp(a), a single subcutaneous dose of FB7023 produced potent and sustained suppression of both PCSK9 and Lp(a) simultaneously. Maximum inhibition reached 68% for PCSK9 and 96% for Lp(a), with effects persisting for more than 12 weeks, suggesting the potential for twice-yearly dosing in humans. The LDL-C reduction by FB7023 was comparable to that of Inclisiran. Concurrently the Lp(a)-lowering efficacy was comparable to that of Olpasiran, achieving the goal of "kill two birds with one stone". Frontier Biotech is advancing FB7023 development in IND-enabling studies and plans to file an IND by the end of 2026.

Expert Commentary

Professor Yong Huo, M.D., Chief Expert and Director of Cardiology at Peking University First Hospital, stated: "The preclinical data for this dual-target siRNA drug candidate are of great interest to the field. Cardiovascular disease (CVD) is the leading non-communicable chronic disease worldwide and the primary cause of death globally, with ASCVD—including ischemic heart disease and ischemic stroke—accounting for the dominant share. Epidemiological, genetic, and clinical intervention studies have fully established LDL-C as the major pathogenic risk factor for ASCVD. Although statins, PCSK9 monoclonal antibodies, and siRNA therapies such as Inclisiran have significantly improved LDL-C management, residual cardiovascular risk remains a prominent concern. Elevated Lp(a) is recognized as an independent risk factor for ASCVD that is mainly determined by genetic factors. Therefore, reducing both LDL-C and Lp(a) has become an important clinical goal for decreasing ASCVD risk. The dual-target siRNA drug FB7023 represents a significant and differentiated innovation in the cardiovascular and lipid metabolism field. Its design concept of concurrently intervening two independent risk factors—LDL-C and Lp(a)—holds significant clinical translational value. The preclinical data preliminarily validated the drug's potent and sustained lipid-lowering potential in both LDL-C and Lp(a) reduction, with a mechanism of action that offers potential advantages over single-target interventions. The transition from preclinical data to clinical practice requires further validation through clinical trials. I look forward to the further development of this innovative therapy, potentially providing high-risk ASCVD patients with a more comprehensive and convenient new option for lipid management."

ASCVD is one of the leading fatal chronic diseases globally, affecting a large patient population with high risks of myocardial infarction and stroke progression. According to the National Center for Cardiovascular Diseases, the number of affected individuals in China has reached several hundred million, imposing a heavy burden on families and healthcare system.